Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABI-007 + Carboplatin in Advanced NSCLC
NCT00274443Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Mar 2005
- Primary completion
- Jun 2007
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nab-paclitaxel in non-small cell lung cancer (NSCLC), sponsored by Celgene Corporation. Primary endpoints: Incidence of treatment emergent adverse events and Objective Response Rate. Started Mar 2005; status: completed.
02
Drugs
nab-paclitaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00274443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00274443.